Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue American Journal of Kidney Diseases Année : 2016

Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial

Heike Benes
  • Fonction : Auteur
Markku Partinen
Virpi Rauta
  • Fonction : Auteur
Daniel Rifkin
  • Fonction : Auteur
Elisabeth Dohin
  • Fonction : Auteur
Nadine Goldammer
  • Fonction : Auteur
Erwin Schollmayer
  • Fonction : Auteur
Hanna Schröder
  • Fonction : Auteur
John Winkelman
  • Fonction : Auteur


BACKGROUND: Restless legs syndrome (RLS) has been associated with insomnia, decreased quality of life, and increased morbidity and mortality in end-stage renal disease. This randomized controlled trial investigated effects of rotigotine in patients with RLS and end-stage renal disease. STUDY DESIGN: Double-blind placebo-controlled study. SETTING & PARTICIPANTS: Adults with moderate to severe RLS (International RLS Study Group Rating Scale [IRLS] ≥ 15) and Periodic Limb Movement Index (PLMI) ≥ 15 who were receiving thrice-weekly hemodialysis enrolled from sites in the United States and Europe. INTERVENTION: Following randomization and titration (≤21 + 3 days) to optimal-dose rotigotine (1-3mg/24 h) or placebo, patients entered a 2-week maintenance period. Polysomnography was performed at baseline and the end of maintenance. OUTCOMES & MEASUREMENTS: Primary efficacy outcome: reduction in PLMI, assessed by ratio of PLMI at end of maintenance to baseline. Secondary/other outcomes (P values exploratory) included mean changes from baseline in PLMI, IRLS, and Clinical Global Impression item 1 (CGI-1 [severity of illness]) score. RESULTS: 30 patients were randomly assigned (rotigotine, 20; placebo, 10); 25 (15; 10) completed the study with evaluable data. Mean (SD) PLMI ratio (end of maintenance to baseline) was 0.7±0.4 for rotigotine and 1.3±0.7 for placebo (analysis of covariance treatment ratio, 0.44; 95% CI, 0.22 to 0.88; P=0.02). Numerical improvements were observed with rotigotine versus placebo in IRLS and CGI-1 (least squares mean treatment differences of -6.08 [95% CI, -12.18 to 0.02; P=0.05] and -0.81 [95% CI, -1.94 to 0.33; P=0.2]). 10 of 15 rotigotine and 2 of 10 placebo patients were CGI-1 responders (≥50% improvement). Hemodialysis did not affect unconjugated rotigotine concentrations. The most common adverse events (≥2 patients) were nausea (rotigotine, 4 [20%]; placebo, 0); vomiting (3 [15%]; 0); diarrhea (1 [5%]; 2 [20%]); headache (2 [10%]; 0); dyspnea (2 [10%]; 0); and hypertension (2 [10%]; 0). LIMITATIONS: Small sample size and short duration. CONCLUSIONS: Rotigotine improved periodic limb movements and RLS symptoms in the short term among ESRD patients requiring hemodialysis in a small-scale study. No dose adjustments are necessary for hemodialysis patients.

Dates et versions

hal-01880785 , version 1 (25-09-2018)



Yves Dauvilliers, Heike Benes, Markku Partinen, Virpi Rauta, Daniel Rifkin, et al.. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2016, 68 (3), pp.434 - 443. ⟨10.1053/j.ajkd.2015.12.027⟩. ⟨hal-01880785⟩
143 Consultations
0 Téléchargements



Gmail Facebook X LinkedIn More